RSS Feeds
Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from Azathioprine
- Alison J. Black, MB, ChB;
- Howard L. McLeod, PharmD;
- Hillary A. Capell, MB, ChB, MD, FRCP;
- Robert H. Powrie, BSc;
- Lloyd K. Matowe, MSc;
- Stuart C. Pritchard, MSc;
- Elaina S.R. Collie-Duguid, PhD; and
- David M. Reid, MB, ChB, MD, FRCP
- From the University of Aberdeen and Aberdeen Royal Hospitals Trust and Glasgow Royal Infirmary, Glasgow, United Kingdom. Acknowledgments: The authors thank research nurse Rosemary Hampson. Grant Support: In part by the Wellcome Trust (046607) and the Beit Trust. Dr. Reid is also supported by the Arthritis Research Campaign. Requests for Reprints: Howard L. McLeod, PharmD, Department of Medicine & Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, United Kingdom; e-mail, h.l.mcleod@abdn.ac.uk. Current Author Addresses: Dr. Black: The Osteoporosis Research Unit, Aberdeen Royal Hospitals Trust, Aberdeen AB25 2ZD, United Kingdom.
Abstract
Background: Substantial hematologic toxicity limits the use of azathioprine.
Objective: To evaluate 1) polymorphic inactivation of azathioprine by thiopurine methyltransferase and 2) clinical toxicity.
Design: Prospective cohort study.
Setting: Two rheumatology units.
Patients: 67 patients for whom azathioprine was prescribed as second-line therapy for rheumatic disease.
Measurements: Polymerase chain reaction-based assays were used to detect mutations in thiopurine methyltransferase. The primary end point was discontinuation of azathioprine therapy because of toxicity.
Results: Six of 67 patients (9%) were heterozygous for mutant thiopurine methyltransferase alleles. Five of the 6 patients discontinued therapy within 1 month of starting treatment because of low leukocyte counts. The sixth patient did not adhere to treatment. Patients with wild-type thiopurine methyltransferase alleles received therapy longer than did patients with mutant alleles (median duration of therapy, 39 weeks [range, 6 to 180 weeks] and 2 weeks [range, 2 to 4 weeks], respectively; P = 0.018).
Conclusion: Analysis of thiopurine methyltransferase genotype is a quick way to identify patients at risk for acute toxicity from azathioprine.
Azathioprine has demonstrated disease-modifying activity in rheumatic disease and is an effective therapy for inflammatory bowel disease, multiple sclerosis, systemic vasculitis, chronic hepatitis, dermatologic disorders, and immunosuppression after solid-organ transplantation [1-6]. However, its use has been limited by a high incidence of hematologic toxicity and concern about long-term side effects [7]. Azathioprine is a relatively inexpensive therapeutic agent for common diseases, and methods for prospectively identifying patients at risk for acute toxicity may be useful for therapeutic decision making.
Azathioprine is converted to 6-mercaptopurine in vivo, where it is metabolized to cytotoxic thioguanine nucleotides or is inactivated by xanthine oxidase or thiopurine methyltransferase. Thiopurine methyltransferase-catalyzed S-methylation shunts thiopurine to relatively inactive compounds and away from activation to thioguanine nucleotides [7]. Population studies have found activity of thiopurine methyltransferase in erythrocytes to be trimodal: Approximately 90% of persons have high activity, 10% have intermediate activity, and 0.3% have low or no activity [8]. Azathioprine-induced bone marrow suppression was more frequent in patients with a dermatologic condition and the intermediate phenotype, whereas patients with high thiopurine methyltransferase activity had a poor clinical response [6]. Patients with low thiopurine methyltransferase activity have severe or fatal hematopoietic toxicity in response to thiopurine-based therapies [7, 9]. However, azathioprine also induces activity of thiopurine methyltransferase in erythrocytes, making direct assessment of enzyme activity difficult [10].
The recent identification of three distinct thiopurine methyltransferase mutations (detected in 80% to 95% of white persons with low or intermediate thiopurine methyltransferase activity) has allowed the development of polymerase chain reaction (PCR)-based techniques for genotype analysis [11]. The most common variant allele in white persons contains point mutations at nucleotides 460 and 719 and has been named TPM*3A [11]. Alleles containing a mutation at nucleotide 238 are designated TPM*2 [11]. This discovery led to the hypothesis that molecular analysis of thiopurine methyltransferase may be a useful way to identify patients at risk for toxicity from thiopurine medication.
Methods
Patients
Thiopurine methyltransferase genotype was assessed in consecutive patients who were seen at the rheumatology departments of the Aberdeen Royal Infirmary or the Glasgow Royal Infirmary in Glasgow, United Kingdom, over a 6-month period and were prescribed azathioprine. No patients were excluded on the basis of previous or current medication. Patients received azathioprine, 2 to 3 mg/kg of body weight per day, as second-line therapy; some patients were also prescribed oral corticosteroids. The patients had received stable doses of nonsteroidal anti-inflammatory drugs as first-line therapy. Blood counts and liver function test results were regularly monitored at least monthly. Reasons for discontinuation of azathioprine therapy were intolerance, progressively abnormal liver function test results, and reduction in total leukocyte count to less than 3.5 × 109/L or reduction in neutrophil count to less than 1.5 × 109/L. Clinicians caring for the patients were unaware of the thiopurine methyltransferase genotype.
Analysis of Thiopurine Methyltransferase Genotype
After patients gave written informed consent, genomic DNA was extracted from 5 mL of whole blood and was analyzed for the presence of mutations at nucleotides 238, 460, and 719 by using allele-specific PCR or PCR restriction fragment length polymorphism, as described elsewhere [11, 12]. In brief, mutation-specific PCR was performed by using pairs of oligonucleotides that specifically amplified a PCR product in the presence of guanine (wild-type allele) or cytosine (mutant allele) at nucleotide 238 [11, 12]. Diagnostic assays for the other alleles took advantage of alterations in the presence of a restriction enzyme cut-site when mutations occurred at nucleotides 460 or 719 [11, 12]. Molecular analysis was done without knowledge of clinical outcome, and both positive and negative (no DNA) controls were included in each assay.
Statistical Analysis
Differences in the duration of therapy between patients with wild-type alleles and those with mutant alleles was assessed by the log-rank test, accompanied by Kaplan-Meier curves.
Results
All 67 patients recruited for this study (55 women and 12 men; mean age ±SD, 51 ± 13.4 years) were evaluable for toxicity and duration of therapy. Azathioprine was used for rheumatoid arthritis (n = 49), systemic lupus erythematosus (n = 7), or other rheumatic diseases (n = 11). Therapy was discontinued in 25 patients (37%) because of side effects (nausea, abnormal liver function test results, and low leukocyte count) and in 18 patients (27%) because of lack or loss of efficacy. Six patients (9%) were heterozygous for TPM*3A; TPM*2 was not detected in this study sample. No patients were homozygous for low-activity thiopurine methyltransferase alleles. Of the 6 patients heterozygous for TPM*3A, 5 discontinued azathioprine therapy within 1 month of starting this therapy because of reduced total leukocyte counts (range, 0.9 to 2.7 × 109/L) (Figure 1). The sixth patient had a well-documented history of noncompliance with drug therapy and on subsequent questioning was found not to be taking azathioprine.
Duration of therapy was significantly longer for patients with wild-type thiopurine methyltransferase alleles (median, 39 weeks [range, 6 to ≥ 180 weeks]) than for those with mutant alleles (median, 2 weeks [range, 2 to 4 weeks]) (P = 0.018). Within the first 2 months of therapy, liver function test results were abnormal in 6 patients with wild-type thiopurine methyltransferase alleles and 1 patient with mutant alleles. All other side effects were mild; the most frequent side effect was gastrointestinal upset. No hematologic abnormalities occurred in patients with wild-type alleles.
Discussion
Our study provides the first analysis of thiopurine methyltransferase genotype in patients with rheumatic disease and identifies the incidence of heterozygous genotype in this population. The clinical significance of this finding is shown in Figure 1: All patients with mutant thiopurine methyltransferase alleles were forced to discontinue azathioprine therapy within 1 month of initiating therapy because of serious hematologic side effects. The rate of abnormal liver function test results caused by azathioprine therapy was not associated with mutant alleles. These data strongly suggest that prospective analysis of thiopurine methyltransferase genotype may allow pretherapy identification of patients at risk for serious toxicity from azathioprine. Azathioprine therapy is active in patients with various inflammatory disorders and may still be useful in patients with variant thiopurine methyltransferase genotypes. However, substantial reductions in azathioprine dosage would be required [7].
Polymerase chain reaction-based assays are routinely used in many laboratory medicine departments; this availability facilitates the use of molecular therapeutic tests, such as thiopurine methyltransferase genotyping. Use of this approach may be appropriate from a health economic standpoint; at our center, for example, the cost of blood monitoring and supportive care exceeds that of PCR analysis by several-fold. This suggests that analysis of all azathioprine recipients to identify the 10% of the population at risk for thiopurine methyltransferase-mediated toxicity would be cost-effective. However, each individual center would need to verify this.
Our study shows the ability of molecular analysis of thiopurine methyltransferase to identify patients at risk for hematologic toxicity from azathioprine. The use of such a test to avoid harmful, and potentially fatal, side effects is especially important because azathioprine is primarily used in ambulatory patients who do not have a terminal illness.
Genotype analysis of thiopurine methyltransferase does not consider other variables regulating in vivo azathioprine activity, such as activation to thiopurine nucleotides, inactivation by xanthine oxidase, or dephosphorylation by 5′-nucleotidase [13]. Assessment of the activity of thiopurine methyltransferase in erythrocytes may also prove useful. This testing will identify patients with high thiopurine methyltransferase activity who are resistant to therapy because thiopurine is shunted away from activation to thioguanine nucleotides [6, 14]. Alternatively, thioguanine nucleotides could be directly measured to determine the quantity of active metabolites formed, thereby predicting the dose necessary for clinical effectiveness [7]. However, only a few research centers have assays for enzyme activity or thioguanine nucleotides; this limits the widespread application of these assays as a screening test for azathioprine.
Analysis of thiopurine methyltransferase genotype is a quick and relatively inexpensive way to identify patients at risk for acute toxicity from azathioprine and should also be applicable to related thiopurine drugs, such as 6-mercaptopurine. It may be a helpful tool for the clinical management of the many patients treated with azathioprine for inflammatory disorders.
Drs. McLeod, Collie-Duguid, and Reid, Mr. Powrie, Mr. Matowe, and Mr. Pritchard: Department of Medicine & Therapeutics, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, United Kingdom.
Dr. Capell: Centre for Rheumatic Disease, Glasgow Royal Infirmary, Glasgow G31 2ER, United Kingdom.
- Copyright ©2004 by the American College of Physicians
